1. Home
  2. GH vs GNTX Comparison

GH vs GNTX Comparison

Compare GH & GNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Guardant Health Inc.

GH

Guardant Health Inc.

HOLD

Current Price

$94.68

Market Cap

13.3B

Sector

Health Care

ML Signal

HOLD

Logo Gentex Corporation

GNTX

Gentex Corporation

HOLD

Current Price

$21.71

Market Cap

5.0B

ML Signal

HOLD

Company Overview

Basic Information
Metric
GH
GNTX
Founded
2011
1974
Country
United States
United States
Employees
N/A
N/A
Industry
Medical Specialities
Auto Parts:O.E.M.
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
13.3B
5.0B
IPO Year
2018
1995

Fundamental Metrics

Financial Performance
Metric
GH
GNTX
Price
$94.68
$21.71
Analyst Decision
Strong Buy
Buy
Analyst Count
19
6
Target Price
$121.11
$28.33
AVG Volume (30 Days)
1.6M
1.8M
Earning Date
04-29-2026
04-24-2026
Dividend Yield
N/A
2.20%
EPS Growth
6.74
N/A
EPS
N/A
1.74
Revenue
$982,021,000.00
$2,534,268,965.00
Revenue This Year
$33.40
$6.70
Revenue Next Year
$28.32
$4.47
P/E Ratio
N/A
$12.55
Revenue Growth
32.88
9.55
52 Week Low
$36.36
$20.28
52 Week High
$120.74
$29.38

Technical Indicators

Market Signals
Indicator
GH
GNTX
Relative Strength Index (RSI) 56.38 46.62
Support Level $89.32 $21.69
Resistance Level $103.16 $22.21
Average True Range (ATR) 3.74 0.46
MACD 1.38 0.14
Stochastic Oscillator 91.16 77.02

Price Performance

Historical Comparison
GH
GNTX

About GH Guardant Health Inc.

Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced-stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant Omni, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.

About GNTX Gentex Corporation

Gentex was founded in 1974 to produce smoke-detection equipment. The company sold its first glare-control interior mirror in 1982 and its first model using electrochromic technology in 1987. Automotive revenue is about 98% of total revenue. The company is constantly developing new applications for the technology to remain on top. Sales in 2024 totaled about $2.3 billion, with 47.7 million mirrors shipped. The unit mix breaks out as 63% interior and 37% exterior, versus 31% exterior in 2019. The company is based in Zeeland, Michigan.

Share on Social Networks: